Limosilactobacillus Fermentun ZS09可以通过调节脑肠功能来改善小鼠抗生素诱导的运动功能障碍
Yang Yang1, Yuanji Zhao2, Huan Lei1
1College of Physical Education, Chengdu Sport University, Chengdu, Sichuan, 610041, People's Republic of China.
Journal of inflammation research
|December 5, 2024
概括
益生菌治疗Limosilactobacillus fermentum ZS09 (LFZS09) 改善了小鼠抗生素诱导的运动障碍的运动功能. LFZS09恢复了肠道微生物群平衡,增强了神经营养因子,为运动功能增强提供了潜力.
科学领域:
- 微生物学与神经科学 微生物学与神经科学
- 肠道微生物组研究研究
- 益生菌治疗药物 益生菌治疗药物
背景情况:
- 益生菌,即活微生物,在适当消耗时,为健康带来好处.
- 抗生素的使用可以破坏肠道微生物群,可能导致运动障碍.
- 利莫西拉科巴西勒斯发酵ZS09 (LFZS09) 是一种益生菌菌株,具有潜在的治疗应用.
研究的目的:
- 在小鼠模型中研究Limosilactobacillus fermentum ZS09 (LFZS09) 对抗生素诱导的运动障碍的预防作用.
- 评估LFZS09对小鼠运动功能,肠道微生物群和神经炎症的影响.
主要方法:
- 建立了抗生素诱导的运动障碍症的小鼠模型.
- 评估血清和脑组织中的运动功能 (跑步,游泳),氧化应激标志物 (MDA,SOD) 和炎症细胞因子 (IL-6,TNF-α).
- 评估肠道屏障基因表达 (occludin-1,ZO-1,claudin-1) 在脑皮组织中和神经营养因子通路基因表达 (CREB,ERK,BDNF) 在脑组织中.
- 对肠道微生物群组成的分析 (Lactobacillus,Bifidobacterium,Enterococcus,Clostridium perfringens). 肠道微生物群组成的分析.
主要成果:
- 在小鼠中,LFZS09显著改善了运动功能,增加了跑步和游泳时间.
- LFZS09降低了炎症因子 (TNF-α,IL-6) 和氧化应激标志物 (MDA) 的水平,同时增加了SOD表达.
- LFZS09提高了肠道屏障基因的调节,增强了BDNF通路基因表达,并调节了肠道微生物群组成,增加了有益的细菌,减少了有害的细菌.
结论:
- 在小鼠中,LFZS09显示出对抗生素诱导的运动障碍有显著的预防作用.
- LFZS09通过保持肠道屏障完整性,增强神经营养支持和重新平衡肠道微生物群来起作用.
- 这些发现为开发基于LFZS09的增强运动功能的益生菌提供了理论基础.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
Drugs Affecting GI Tract Motility: Other Laxatives
169
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
169
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
209
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
209
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
186
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
186


